Skip to main content

White William Richard's Form 4 filing

Akero Therapeutics, Inc. (AKRO) · filed Dec 29, 2022

Accession no.
0000899243-22-039531
Filed
Dec 29, 2022
Trade date
Dec 27-28, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $995.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
White William RichardCIK 0001778739Officer (Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 27, 2022Common StockMOption exerciseAcquired+19,001$7.01+$133,197.0142,625Direct
Dec 27, 2022Common StockSSaleDisposed−19,001$49.77F2−$945,679.7723,624Direct
Dec 28, 2022Common StockMOption exerciseAcquired+999$7.01+$7,002.9924,623Direct
Dec 28, 2022Common StockSSaleDisposed−999$49.76F3−$49,710.2423,624Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 27, 2022Common StockMOption exerciseDisposed−19,001$0.00$0242,828Direct
Dec 28, 2022Common StockMOption exerciseDisposed−999$0.00$0241,829Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.75 to $49.84, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.

Referenced by the price of 1 transaction in Table I.

F3

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.75 to $49.785, inclusive.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)